This is a clinical stage biopharmaceutical company is engaged in the research and development of novel agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. Nabriva is developing both intravenous and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intends to develop lefamulin for additional indications other than pneumonia.
The company has completed a Phase 2 clinical trial of lefamulin for acute bacterial skin and skin structure infections (ABSSSI). Based on the clinical results of lefamulin for ABSSSI, as well as its rapid tissue distribution, including substantial penetration into lung tissue and fluids, the company is preparing to initiate two international, pivotal Phase 3 clinical trials of lefamulin for the treatment of moderate to severe CABP. These will be the first clinical trials the company has conducted with lefamulin for the treatment of CABP.
ALSO READ: Jefferies Franchise Pick Stocks to Buy That Also Pay Big Dividends
A few analysts weighed in on Nabriva following the end of the quiet period:
- Wedbush initiated coverage with an Outperform rating and a $17 price target.
- Leerink initiated coverage with an Outperform rating and a $19 price target.
- RBC Capital initiated coverage with an Outperform rating and a $21 price target.
- Needham initiated coverage with a Buy rating and a $15 price target.
Shares of Nabriva were about flat at $9.99 in late morning trading Tuesday, after dropping as low as $9.81 earlier in the day. The stock has a post-IPO trading range of $8.75 to $14.82.
Top Gaining Stocks
Top Losing Stocks